Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Serum microRNAs as potential biomarkers for lung cancer

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Hye-Young Lee

Citation

Annals of Oncology (2015) 26 (suppl_9): 148-152. 10.1093/annonc/mdv533

Authors

H. Lee1, S. Song1, K. Lim2, C. Park3

Author affiliations

  • 1 Internal Medicine, Kangwon National University Hospital, 200-701 - Chuncheon/KR
  • 2 Internal Medicine, Kangwon National University Hospital, 200-722 - Chuncheon/KR
  • 3 Emergency Medicine, Kangwon National University Hospital, 200-701 - Chuncheon/KR
More

Resources

Aim/Background

MicroRNAs (miRNAs) are single-stranded RNA species that constitute a class of non-coding RNAs, and are emerging as key regulators of gene expression.In our previous study, we identified significantly differentially expressed miRNAs and mRNAs between lung cancer and normal tissue by means of massively parallel sequencing. In this study, we investigated serum miRNA expression to compare non-small-cell lung cancer (NSCLC) patients and controls by our previous studied miRNA profiles.

Methods

This study involved RNA isolation from 184 sera specimens including those from lung cancer patients and age- and gender-matched controls (n = 92 each). Serum RNA was isolated with miRNeasy Serum/Plasma Kit (Qiagen), and reverse transcription was performed using the miScript II RT Kit (Qiagen) according to the manufacturer's instructions. cDNA of microRNA was amplified using the miScript miRNA PCR Array as follows:let-7c-5p, miR-21-5p,miR1-3p,miR-133a-3p, miR-139-5p, miR-144-5p, miR-182-5p, miR-196a-5p, miR-196b-5p,205-5p,miR-210-3p, miR-301b-3p, miR-30a-3p, miR-338-3p, miR-490-3p,miR-577, miR-615-3p,miR-891a-5p, miR-944, miR-1246, and for internal control mir-191-3p (Qiagen). The data were analyzed using the PCR array data analysis tools (Qiagen). Appropriate informed consent was obtained from the participants, and the Institutional Review Board of the Kangwon National University Hospital (Chuncheon, Korea) approved the study.

Results

miR-21-5p, miR-144-5p, miR-182-5p, miR-205-5p, miR-891a-5p and miR-1246 was found to be present at substantially higher levels in lung cancer compared with control sera, as indicated by an absolute fold change ≥1.0 and P < 0.05. And miR-1246 was most significantly higher level in in lung cancer compared with control sera (fold change = 5.6, p-value < 0.05).

Conclusions

Differences in miRNA profile identified support circulating miRNA s having potential as diagnostic biomarkers for lung cancer. More extensive studies of lung cancer and control serum specimens are warranted to independently validate the potential clinical relevance of these miRNA s as minimally invasive biomarkers for lung cancer.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings